Development of UGN-301 (zalifrelimab) to discontinue following completion of Ph 1 dose escalation study November 10, 2025
Enrollment Completed in SAFFRON Ph 3 Trial of ORPATHYS + TAGRISSO Combo in TAGRISSO-treated EGFRm, MET-overexpressed and/or amplified LA/M NSCLC patients November 10, 2025
Following discussion with FDA, safusidenib vs vorasidenib trial in grade 2 IDH1-mutant glioma cancelled November 10, 2025
DESTINY-Lung06 Ph 3 Trial of ENHERTU Initiated as 1L Therapy in Patients with HER2 Overexpressing Metastatic NonSquamous NSCLC November 4, 2025
First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer November 4, 2025
Independent DSMB recommends continuation of pivotal Ph 3 study of Bria-IMT™ + immune CPI in metastatic breast cancer October 25, 2025
First Patient Enrolled in Ph 1 Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 October 21, 2025
First patients enrolled in Ph 1 trial with KQB548 (BAY 3771249) in KRAS G12D-mutated tumors October 21, 2025
Ivonescimab Global Ph 3 Development Program with HARMONi-GI3 Study expanded in 1L CRC October 21, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Initiation of Ph 1/2 study of AVZO-103 in patients with advanced solid tumors announced October 8, 2025
First Patient Enrolled in TRUST-IV Ph 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of Early-Stage ROS1+ve NSCLC October 8, 2025
Initial clinical data for BDC-4182 Ph 1 dose escalation study now expected in 3Q 2026 October 7, 2025
First patient with follicular lymphoma (FL) dosed in CELESTIAL-301 Ph 1 trial of SynKIR™-310 October 4, 2025
Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned September 30, 2025
